Endeavour Vision

Endeavour Vision SA, established in 2000, is a Geneva-based venture capital firm focusing on growth-stage investments in the technology and healthcare sectors, with a particular emphasis on medical technology and digital health. The company invests in Europe, the United States, and the Middle East, typically providing between $5 million and $25 million per portfolio company over the life of the investment. Endeavour Vision seeks to maintain a significant stake, usually between 10% and 25%, and often takes a Board seat. The firm prefers to be the lead or co-lead investor and typically co-invests with other venture capital firms. Endeavour Vision aims to exit its investments within five to ten years, favoring initial public offerings or acquisitions. The firm has a proven track record of successful exits, including Vertiflex and Medartis.

Toby AuWerter

Investment Director

Rob Barmann

Partner

Dominik Ellenrieder

Operating Partner

Fernando Pacheco

Senior Investment Director

67 past transactions

Kestra Medical Technologies

Private Equity Round in 2024
Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices designed for monitoring and managing acute medical conditions. Founded in 2014 and based in Kirkland, Washington, the company offers solutions that collect, communicate, and store patient performance data, enabling both real-time and retrospective analysis. Among its products are wearable cardioverter defibrillators, which aim to prevent sudden cardiac death and facilitate cardiac recovery in at-risk patients. Kestra Medical Technologies focuses on creating intuitive and mobile diagnostic and therapeutic technologies that support healthcare providers and enhance patient care.

Nalu Medical

Series E in 2024
Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.

Gynesonics

Venture Round in 2023
Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Virtual Incision

Series C in 2023
Virtual Incision is focused on developing innovative surgical solutions, specifically through its miniaturized robotic support device designed for colon resection. The company's flagship product, the MIRA (Miniaturized In vivo Robotic Assistant) Platform, is a pioneering device that aims to streamline surgical procedures by allowing for quick setup in the operating room without the need for heavy equipment. This technology is intended to assist surgeons in improving clinical outcomes while also addressing healthcare costs. Virtual Incision's approach represents a significant advancement in robotic-assisted surgery, with plans for future applications beyond colon resection.

Relievant Medsystems

Venture Round in 2023
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

Venture Med Group

Convertible Note in 2023
VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Miach Orthopaedics

Series B in 2023
Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, founded in 2016. The company specializes in developing bio-engineered surgical implants aimed at facilitating new tissue growth and aiding in connective tissue repair. Its primary product, the Bridge-Enhanced ACL Repair technology, offers a viable alternative to traditional anterior cruciate ligament (ACL) reconstruction for patients who have suffered ACL injuries. This innovative approach enables surgeons to restore the normal anatomy and function of the knee, enhancing recovery outcomes for patients.

HealthJoy

Series D in 2022
HealthJoy, LLC operates an online healthcare decision platform that aims to reduce out-of-pocket expenses for consumers by enabling better healthcare decisions. Founded in 2014 and based in Chicago, the company focuses on enhancing the benefits experience for employees while assisting organizations in managing costs. Through personalized guidance and AI-driven technology, HealthJoy provides employees with a digital benefits wallet that integrates their existing benefits, ensuring they remain informed about their options. The platform offers on-demand access to online medical consultations, healthcare concierges, and prescription savings, empowering users to make educated choices about their healthcare. By simplifying the healthcare experience and offering insights into cost-effective care options, HealthJoy helps employees improve their satisfaction and reduces the burden on human resources.

IntelyCare

Series C in 2022
IntelyCare, Inc. is a healthcare staffing company based in Quincy, Massachusetts, founded in 2014. It provides an on-demand staffing platform that connects nursing professionals with post-acute healthcare facilities, enabling them to optimize staffing levels and manage workforce demands effectively. The platform allows nurses and nursing assistants to create their own schedules and select shifts that suit them, fostering a flexible work environment. Utilizing advanced data science and artificial intelligence, IntelyCare automates scheduling and improves the efficiency of filling nursing shifts, achieving rates three times the industry average. The company serves a variety of clients, including home care agencies, assisted living facilities, long-term care establishments, and rehabilitation hospitals, ultimately aiming to reduce burnout among nursing staff and enhance overall productivity. IntelyCare operates as a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC.

Nalu Medical

Venture Round in 2022
Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.

Kenbi

Series A in 2021
Kenbi is a nurse-centric outpatient care company focused on enhancing healthcare delivery by supporting nurses and addressing gaps in the system. It offers outpatient care management services that leverage technology and a collegial organizational structure to organize local care teams. These teams provide at-home services, which may include medical care covered by insurance, household assistance, advice, and companionship. By streamlining operations and reducing bureaucratic burdens, Kenbi enables healthcare practitioners to devote more time to patient care, thus improving the overall experience for patients and their families.

V-Wave

Series C in 2021
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Virtual Incision

Series C in 2021
Virtual Incision is focused on developing innovative surgical solutions, specifically through its miniaturized robotic support device designed for colon resection. The company's flagship product, the MIRA (Miniaturized In vivo Robotic Assistant) Platform, is a pioneering device that aims to streamline surgical procedures by allowing for quick setup in the operating room without the need for heavy equipment. This technology is intended to assist surgeons in improving clinical outcomes while also addressing healthcare costs. Virtual Incision's approach represents a significant advancement in robotic-assisted surgery, with plans for future applications beyond colon resection.

Venture Med Group

Convertible Note in 2021
VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Inbrace

Series D in 2021
Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

Willow

Series C in 2021
Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

CeQur Simplicity

Series C in 2021
CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Relievant Medsystems

Venture Round in 2020
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

SOPHiA GENETICS

Series F in 2020
SOPHiA GENETICS is a healthcare technology company specializing in data-driven medicine. It offers the SOPHiA DDM™ Platform, a cloud-based SaaS solution that analyzes complex multimodal datasets from various diagnostic modalities to generate insights. With over 780 global clients, including hospitals, laboratories, and biopharma institutions across three continents, the company aims to make data-driven medicine the standard of care in healthcare and life sciences research.

V-Wave

Series C in 2020
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Lumeon

Series D in 2020
Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and formerly known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time overview of the patient journey from referral to outcome. The company's services encompass business analysis, project management, configuration, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon enables healthcare providers to unify clinical and administrative workflows, automate tasks, and achieve measurable healthcare outcomes. Its client base includes some of Europe's leading healthcare providers, such as BUPA, Nuffield Health, and HCA, reflecting the company's role in driving healthcare transformation.

Polares Medical

Series B in 2020
Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Rapid Micro Biosystems

Venture Round in 2020
Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

IntelyCare

Series B in 2020
IntelyCare, Inc. is a healthcare staffing company based in Quincy, Massachusetts, founded in 2014. It provides an on-demand staffing platform that connects nursing professionals with post-acute healthcare facilities, enabling them to optimize staffing levels and manage workforce demands effectively. The platform allows nurses and nursing assistants to create their own schedules and select shifts that suit them, fostering a flexible work environment. Utilizing advanced data science and artificial intelligence, IntelyCare automates scheduling and improves the efficiency of filling nursing shifts, achieving rates three times the industry average. The company serves a variety of clients, including home care agencies, assisted living facilities, long-term care establishments, and rehabilitation hospitals, ultimately aiming to reduce burnout among nursing staff and enhance overall productivity. IntelyCare operates as a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC.

Nuvaira

Series E in 2019
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

Polares Medical

Series A in 2018
Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Relievant Medsystems

Series E in 2018
Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

V-Wave

Series C in 2018
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Gynesonics

Private Equity Round in 2018
Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Venture Med Group

Series B in 2017
VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Vertiflex

Venture Round in 2017
Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Chrono Therapeutics

Series B in 2016
Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, specializing in digital transdermal drug delivery systems. Founded in 2003, the company has developed SmartStop, a digital nicotine replacement therapy that incorporates a wearable device. This innovative solution allows for programmable delivery of nicotine, adjusting timing and dosage to effectively manage withdrawal symptoms and peak addiction triggers. By combining this transdermal therapy with real-time behavioral support, Chrono Therapeutics aims to enhance smoking cessation efforts and improve clinical outcomes for users. The leadership team brings extensive experience in product development, research and development, and a deep understanding of the smoking cessation market, positioning the company to play a significant role in addressing the smoking epidemic.

EndoStim

Series D in 2016
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.

CeQur Simplicity

Series C in 2015
CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

ReShape Medical

Series D in 2015
ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

Gynesonics

Venture Round in 2015
Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Kobojo

Series B in 2015
Kobojo is a French startup established in 2008 that focuses on developing online games and applications aimed at engaging mid-core players. The company enhances traditional gaming experiences by incorporating a social dimension, allowing players to connect and compete with friends. Kobojo's offerings are accessible on various platforms, primarily through social networks, without the need for downloads. The games feature hand-drawn 2D graphics that provide an artistic flair, appealing to users who appreciate creative visuals. While currently available on platforms like Facebook and iPhone, Kobojo plans to expand its reach to additional social networks in the future.

SOPHiA GENETICS

Series B in 2014
SOPHiA GENETICS is a healthcare technology company specializing in data-driven medicine. It offers the SOPHiA DDM™ Platform, a cloud-based SaaS solution that analyzes complex multimodal datasets from various diagnostic modalities to generate insights. With over 780 global clients, including hospitals, laboratories, and biopharma institutions across three continents, the company aims to make data-driven medicine the standard of care in healthcare and life sciences research.

Amplidata

Series D in 2014
Amplidata develops advanced storage technology designed to enhance data reliability and efficiency. Its innovative BitSpread encoding technology offers a highly scalable and user-friendly alternative to traditional RAID systems, boasting a reliability that is ten thousand times greater. This solution not only requires three times less storage and power, but also significantly reduces costs, making it five times cheaper than existing options. Amplidata's products, including the AmpliStor object-based software-defined storage system, cater to both private and hyper-scale public cloud environments, addressing critical challenges such as performance, error rates, and system failures. Founded in 2008 by experienced industry professionals Wim De Wispelaere and Wouter Van Eetvelde, along with investor Kristof De Spiegeleer, Amplidata operates from its headquarters in Lochristi, Belgium, with research and development facilities in both Belgium and Egypt, and a sales presence across Europe and North America.

Quid

Convertible Note in 2013
Quid, Inc. develops a platform that searches, analyzes, and visualizes collective intelligence to address strategic inquiries. Its software specializes in analyzing text-based data, utilizing advanced techniques such as implicit network analysis and graph theory to create interactive visualizations. Through proprietary algorithms that incorporate artificial intelligence and natural language processing, Quid efficiently uncovers insights from extensive datasets, including news articles, blog posts, company profiles, and patents. The platform is designed for non-technical users in enterprise organizations, enabling them to independently access valuable information and generate unique insights. Quid caters to various sectors, including marketing, public relations, consulting, technology, healthcare, and financial services. Founded in 2006 and headquartered in San Francisco, California, with additional offices in New York and London, Quid merged with NetBase Solutions in January 2020, forming a combined entity known as NetBase Quid.

OncoEthix

Series B in 2013
Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Spartoo

Series C in 2012
Spartoo is a European online retailer based in Grenoble, France, specializing in the sale of footwear and fashion items. Founded in 2006, the company offers an extensive range of products, including shoes for men, women, and children, such as trainers, boots, sandals, and various styles of footwear. In addition to shoes, Spartoo also sells ready-to-wear apparel, leather goods, and related accessories, providing a comprehensive shopping experience for its customers. The company's e-commerce platform serves markets in several countries, including Germany, England, Italy, and Spain, as well as the United Kingdom and its offshore islands.

Amplidata

Venture Round in 2012
Amplidata develops advanced storage technology designed to enhance data reliability and efficiency. Its innovative BitSpread encoding technology offers a highly scalable and user-friendly alternative to traditional RAID systems, boasting a reliability that is ten thousand times greater. This solution not only requires three times less storage and power, but also significantly reduces costs, making it five times cheaper than existing options. Amplidata's products, including the AmpliStor object-based software-defined storage system, cater to both private and hyper-scale public cloud environments, addressing critical challenges such as performance, error rates, and system failures. Founded in 2008 by experienced industry professionals Wim De Wispelaere and Wouter Van Eetvelde, along with investor Kristof De Spiegeleer, Amplidata operates from its headquarters in Lochristi, Belgium, with research and development facilities in both Belgium and Egypt, and a sales presence across Europe and North America.

OncoEthix

Series A in 2012
Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Symetis

Series D in 2012
Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Amplidata

Series C in 2012
Amplidata develops advanced storage technology designed to enhance data reliability and efficiency. Its innovative BitSpread encoding technology offers a highly scalable and user-friendly alternative to traditional RAID systems, boasting a reliability that is ten thousand times greater. This solution not only requires three times less storage and power, but also significantly reduces costs, making it five times cheaper than existing options. Amplidata's products, including the AmpliStor object-based software-defined storage system, cater to both private and hyper-scale public cloud environments, addressing critical challenges such as performance, error rates, and system failures. Founded in 2008 by experienced industry professionals Wim De Wispelaere and Wouter Van Eetvelde, along with investor Kristof De Spiegeleer, Amplidata operates from its headquarters in Lochristi, Belgium, with research and development facilities in both Belgium and Egypt, and a sales presence across Europe and North America.

Quid

Series C in 2011
Quid, Inc. develops a platform that searches, analyzes, and visualizes collective intelligence to address strategic inquiries. Its software specializes in analyzing text-based data, utilizing advanced techniques such as implicit network analysis and graph theory to create interactive visualizations. Through proprietary algorithms that incorporate artificial intelligence and natural language processing, Quid efficiently uncovers insights from extensive datasets, including news articles, blog posts, company profiles, and patents. The platform is designed for non-technical users in enterprise organizations, enabling them to independently access valuable information and generate unique insights. Quid caters to various sectors, including marketing, public relations, consulting, technology, healthcare, and financial services. Founded in 2006 and headquartered in San Francisco, California, with additional offices in New York and London, Quid merged with NetBase Solutions in January 2020, forming a combined entity known as NetBase Quid.

Kobojo

Series A in 2011
Kobojo is a French startup established in 2008 that focuses on developing online games and applications aimed at engaging mid-core players. The company enhances traditional gaming experiences by incorporating a social dimension, allowing players to connect and compete with friends. Kobojo's offerings are accessible on various platforms, primarily through social networks, without the need for downloads. The games feature hand-drawn 2D graphics that provide an artistic flair, appealing to users who appreciate creative visuals. While currently available on platforms like Facebook and iPhone, Kobojo plans to expand its reach to additional social networks in the future.

Retailo

Series C in 2011
Retailo is a full-service provider in the prepaid and gift card industry, specializing in the distribution of gift cards across continental Europe. The company operates a third-party prepaid card network, offering a variety of products, including gift cards, virtual gift vouchers, and online shopping cards. These products are conveniently available at multiple points of sale, such as retail stores, flower shops, and petrol stations, allowing customers to purchase gift cards for special occasions. In addition to offline sales, Retailo also provides electronic vouchers that can be delivered via SMS or MMS through its website, catering to the growing demand for digital solutions in the gifting market.

SmallRivers

Series A in 2011
SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.

PneumRx

Venture Round in 2011
PneumRx, Inc. is a medical device company founded in 2004 and based in Mountain View, California. The company specializes in developing minimally invasive treatments specifically for patients suffering from emphysema. Its primary product is the RePneu Lung Volume Reduction Coil, an investigational device designed to improve lung function and quality of life for individuals affected by this chronic respiratory condition.

Symetis

Series C in 2010
Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Amplidata

Series B in 2010
Amplidata develops advanced storage technology designed to enhance data reliability and efficiency. Its innovative BitSpread encoding technology offers a highly scalable and user-friendly alternative to traditional RAID systems, boasting a reliability that is ten thousand times greater. This solution not only requires three times less storage and power, but also significantly reduces costs, making it five times cheaper than existing options. Amplidata's products, including the AmpliStor object-based software-defined storage system, cater to both private and hyper-scale public cloud environments, addressing critical challenges such as performance, error rates, and system failures. Founded in 2008 by experienced industry professionals Wim De Wispelaere and Wouter Van Eetvelde, along with investor Kristof De Spiegeleer, Amplidata operates from its headquarters in Lochristi, Belgium, with research and development facilities in both Belgium and Egypt, and a sales presence across Europe and North America.

Nfocus Neuromedical

Series C in 2010
Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.

BIND Therapeutics

Series C in 2010
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

CXignited

Series D in 2010
CXignited is a provider of a cloud-based platform focused on enhancing customer experience through product digitization and authentication. Its ShopCX Cloud Platform integrates shop floor and unified commerce information using RFID, beacons, and IoT technologies. This innovative platform enables luxury retailers and global brands to achieve real-time visibility into in-store engagement, allowing for improved localization, personalization, and overall customer interaction across various channels. Through its Real-time Local Positioning System, CXignited aims to set a new standard in customer experience by effectively connecting products, people, and brand passion.

Spartoo

Series B in 2010
Spartoo is a European online retailer based in Grenoble, France, specializing in the sale of footwear and fashion items. Founded in 2006, the company offers an extensive range of products, including shoes for men, women, and children, such as trainers, boots, sandals, and various styles of footwear. In addition to shoes, Spartoo also sells ready-to-wear apparel, leather goods, and related accessories, providing a comprehensive shopping experience for its customers. The company's e-commerce platform serves markets in several countries, including Germany, England, Italy, and Spain, as well as the United Kingdom and its offshore islands.

CeQur Simplicity

Series A in 2010
CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Molecular Partners

Series B in 2009
Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

Lumavita

Series A in 2009
Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of innovative anti-infectives aimed at women's health. Founded in 2008, the company offers products such as FemiFect, an antibiotic designed to treat infections associated with vaginitis caused by bacteria, fungi, and protozoa, and SPK-601, which targets human papillomavirus (HPV) and herpes simplex virus (HSV). Lumavita markets its products through various distributors, positioning itself within the expanding biopharmaceutical sector in Switzerland. The company was previously known as Shogoo Pharmaceuticals, AG before rebranding in December 2007 and operates as a subsidiary of Shogoo Pharmaceuticals KK.

CommProve

Venture Round in 2008
CommProve, established in 1996, specializes in real-time Quality of Service (QoS) monitoring for wireless networks. The company, founded by experts in network operations and software engineering, offers a platform that collects, analyzes, and integrates network usage data from various mobile networks. This enables mobile network operators to gain real-time insights into their operations, helping them control financial performance, quality of experience, and network performance.

Retailo

Series B in 2008
Retailo is a full-service provider in the prepaid and gift card industry, specializing in the distribution of gift cards across continental Europe. The company operates a third-party prepaid card network, offering a variety of products, including gift cards, virtual gift vouchers, and online shopping cards. These products are conveniently available at multiple points of sale, such as retail stores, flower shops, and petrol stations, allowing customers to purchase gift cards for special occasions. In addition to offline sales, Retailo also provides electronic vouchers that can be delivered via SMS or MMS through its website, catering to the growing demand for digital solutions in the gifting market.

Retailo

Series A in 2007
Retailo is a full-service provider in the prepaid and gift card industry, specializing in the distribution of gift cards across continental Europe. The company operates a third-party prepaid card network, offering a variety of products, including gift cards, virtual gift vouchers, and online shopping cards. These products are conveniently available at multiple points of sale, such as retail stores, flower shops, and petrol stations, allowing customers to purchase gift cards for special occasions. In addition to offline sales, Retailo also provides electronic vouchers that can be delivered via SMS or MMS through its website, catering to the growing demand for digital solutions in the gifting market.

Molecular Partners

Series A in 2007
Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

CXignited

Series C in 2006
CXignited is a provider of a cloud-based platform focused on enhancing customer experience through product digitization and authentication. Its ShopCX Cloud Platform integrates shop floor and unified commerce information using RFID, beacons, and IoT technologies. This innovative platform enables luxury retailers and global brands to achieve real-time visibility into in-store engagement, allowing for improved localization, personalization, and overall customer interaction across various channels. Through its Real-time Local Positioning System, CXignited aims to set a new standard in customer experience by effectively connecting products, people, and brand passion.

EndoArt

Series C in 2006
EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.

CXignited

Venture Round in 2005
CXignited is a provider of a cloud-based platform focused on enhancing customer experience through product digitization and authentication. Its ShopCX Cloud Platform integrates shop floor and unified commerce information using RFID, beacons, and IoT technologies. This innovative platform enables luxury retailers and global brands to achieve real-time visibility into in-store engagement, allowing for improved localization, personalization, and overall customer interaction across various channels. Through its Real-time Local Positioning System, CXignited aims to set a new standard in customer experience by effectively connecting products, people, and brand passion.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.